Next-generation Sequencing of Colorectal Cancer Somatic Cells to Guide Genetic Susceptibility Gene Mutations Screening.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-06-20

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, single-center, clinical study.This study is to evaluate the feasibility of genetic susceptibility screening based on the detection of tumor tissue mutations by a NGS panel.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Somatic Mutation Spectrum as Biomarker for Survival Outcome in Chinese CRC

NCT04228614

Colorectal Cancer

UNKNOWN

A Cohort of Molecular Characteristics and Prognosis of Colorectal Cancer

NCT05086601

Colorectal Cancer Surgery

UNKNOWN

Circulating Tumor DNA Methylation Guided Postoperative Follow-up Strategy for Non-metastatic Colorectal Cancer

NCT05904665

Non-metastatic Colorectal Cancer Circulating Tumor DNA Methylation

RECRUITING NA

Evaluation of a Model for the Early Diagnosis of Colorectal Cancer by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA to the Community Colorectal Cancer Screening Program

NCT05638243

Colorectal Cancer Colorectal Neoplasms

UNKNOWN

A Multi-center Trial to Establish a Model for the Early Diagnosis of Colorectal Cancer by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA

NCT03676075

Colorectal Cancer Adenoma

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study, gene mutation profiling was performed on primary tissue samples from colorectal cancer patients who met relevant clinical screening criteria, unearthing suspected germline pathogenic mutations. At the same time, germline mutation detection was performed on peripheral blood leukocytes of patients, and the consistency between suspected germline mutations in tumor somatic mutation detection and control leukocytes was compared. Establishing the feasibility of tumor somatic mutation-based detection to guide genetic susceptibility screening.Pedigree verification will be carried out for blood relatives of patients with germline mutations which have been identified for colorectal cancer.Through the tumor somatic and germline gene mutation profiles of Chinese hereditary colorectal cancer patients, it reveals the molecular characteristics of hereditary colorectal cancer in Asian populations and provides molecular-level evidence for possible subsequent clinical diagnosis and treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hereditary Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A biopsy proven histological diagnosis of colorectal carcinoma.
* ≥ 18 years of age on the day of signing informed consent.
* Patients must meet the relevant clinical screening standards, such as the Amsterdam Standard (I / II),etc.
* Patients need to provide tumor tissue samples and matched peripheral blood (leukocyte) samples.

Exclusion Criteria

* History of other malignant tumors(except for cervical carcinoma in situ, basal or squamous cell skin cancer which has been fully treated).
* There is no detailed histopathological report to judge the nature of the lesions.
* Any social or psychological problems, etc., which are judged by the researcher to be unsuitable for the study.
* For various reasons, the baseline samples (tumor tissue samples, peripheral blood samples) were incomplete.
* Patients who are unwilling or unable to follow the research program for long-term and regular follow-up in current medical institutions.
* Failure to complete the follow-up within 2 years.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No